There are 2949 resources available
676P - Prognostic role of nutritional status (NS) for health-related quality of life (HRQoL) in men with advanced prostate cancer
Presenter: Luka Cavka
Session: E-Poster Display
Resources:
Abstract
677P - A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Final analysis
Presenter: Deepak Kilari
Session: E-Poster Display
Resources:
Abstract
678P - Metastasis-directed stereotactic body radiotherapy (SBRT)-guided by PET-CT 18F-choline versus PET-CT 68Ga-PSMA in castration sensitive oligorecurrent prostate cancer: A comparative effectiveness analysis
Presenter: Luca Nicosia
Session: E-Poster Display
Resources:
Abstract
679P - Treatment patterns of metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study
Presenter: Scott Tagawa
Session: E-Poster Display
Resources:
Abstract
680P - Comparative efficacy of first-line novel anti-androgen therapies versus docetaxel in metastatic hormone sensitive prostate cancer (mHSPC): An updated network meta-analysis
Presenter: Philip Haddad
Session: E-Poster Display
Resources:
Abstract
681P - Clinical and immune responses to immunotherapy in biochemically recurrent (non-metastatic castration sensitive) prostate cancer (BCRpc)
Presenter: Ravi Madan
Session: E-Poster Display
Resources:
Abstract
682P - Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer
Presenter: Mark Tuthill
Session: E-Poster Display
Resources:
Abstract
683P - Correlation between castration resistant prostate cancer (CRPC) free survival (CRPC-FS) and metastasis free survival (MFS) in men initiating androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after radical prostatectomy (RP): Results from the SEARCH database
Presenter: Stephen Freedland
Session: E-Poster Display
Resources:
Abstract
684P - The real effects of prostate cancer chemotherapy: Results of the EUPROMs prostate patient-driven quality of life study
Presenter: André Deschamps
Session: E-Poster Display
Resources:
Abstract
685P - A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC): Outcomes by prostate-specific antigen (PSA) response
Presenter: Maha Hussain
Session: E-Poster Display
Resources:
Abstract